Qianhai Health Holdings Ltd. stock analysis
Want to see HK:0911 full AI Analyst Report?
Qianhai Health Holdings Ltd. (0911) Stock Price & Analysis
0911 Stock Chart & Stats
- Day’s Range
- HKD 0.30 - HKD 0.32
- 52-Week Range
- HKD 0.24 - HKD 1.40
- Previous Close
- HKD 0.32
- Volume
- N/A
- Average Volume (3M)
- 45.06K
- Market Cap
- HKD 54.22M
- Enterprise Value
- HKD 90.67M
- Total Cash (Recent Filing)
- HKD 17.88M
- Total Debt (Recent Filing)
- HKD 107.00K
- Price to Earnings (P/E)
- 13.3
- Beta
- 0.10
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 31, 2018
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
The extremely conservative financing structure limits interest and refinancing pressure while preserving financial flexibility. A large equity base gives the company greater capacity to withstand operating volatility, support working capital, and fund future initiatives without materially increasing leverage.
Improved Cash Generation
The sharp improvement in operating and free cash flow indicates that recent profitable operations are translating into internally generated funds. This strengthens liquidity, reduces reliance on external financing, and provides a more durable base for maintaining operations and pursuing growth.
Financial Turnaround
The return to positive earnings and operating profit marks a meaningful recovery from the large losses of 2022–2023. The 2025 revenue rebound also suggests renewed business activity, improving the company’s ability to sustain operations and rebuild earnings power over coming periods.
Bears Say
Very Thin Profitability
Extremely narrow margins leave little room to absorb pricing pressure, cost increases, or weaker demand. The decline from 2024 indicates that the earnings recovery remains fragile, so even modest operating deterioration could materially reduce profit and cash generation.
Volatile Earnings History
The recent recovery follows a materially unstable financial history rather than a long record of consistent profitability. Prior losses and cash burn increase uncertainty around earnings durability and suggest that future results may remain sensitive to changes in operating performance.
Low Capital Efficiency
Positive ROE is an improvement, but a level near 1.5% indicates that the substantial equity base is generating limited returns. Persistently low capital efficiency can constrain sustainable earnings growth and reduce the effectiveness of retained funds.
Qianhai Health Holdings Ltd. News
Qianhai Health Books HK$60.4 Million Onerous Contract Provision on Electronics Products
Qianhai Health Holdings Ltd. ( ($HK:0911) ) has shared an update. Qianhai Health Holdings Limited has issued a supplemental announcement to its 2024 annual results and annual report, disclosing additional
0911 FAQ
What was Qianhai Health Holdings Ltd.’s price range in the past 12 months?
What is Qianhai Health Holdings Ltd.’s market cap?
When is Qianhai Health Holdings Ltd.’s upcoming earnings report date?
How were Qianhai Health Holdings Ltd.’s earnings last quarter?
Is Qianhai Health Holdings Ltd. overvalued?
Does Qianhai Health Holdings Ltd. pay dividends?
What is Qianhai Health Holdings Ltd.’s EPS estimate?
How many shares outstanding does Qianhai Health Holdings Ltd. have?
What happened to Qianhai Health Holdings Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Qianhai Health Holdings Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Qianhai Health Holdings Ltd.
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chee Lap Yuen
- Employees
- 19
- Website
- www.qianhaihealth.com.hk
- Address
- HK
Qianhai Health Holdings Ltd. (0911) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 4 | 15 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |











